Literature DB >> 24769034

GALNT4 predicts clinical outcome in patients with clear cell renal cell carcinoma.

Yidong Liu1, Weisi Liu1, Le Xu2, Haiou Liu1, Weijuan Zhang3, Yu Zhu4, Jiejie Xu5, Jianxin Gu1.   

Abstract

PURPOSE: We investigated the clinical significance of GALNT4 expression in patients with clear cell renal cell carcinoma.
MATERIALS AND METHODS: Enrolled in this study were 104 patients treated with curative nephrectomy at Zhongshan Hospital, Shanghai during 2004. Of the cohort 23 patients died of disease, 33 experienced recurrence and 3 died of another cause. GALNT4 density was assessed by immunohistochemistry in patient specimens. Univariate and multivariate Cox models, and ROC analysis were used to analyze the impact of prognostic factors on overall and relapse-free survival. Kaplan-Meier analysis with the log rank test was done to compare clinical outcomes between subgroups.
RESULTS: Intratumor GALNT4 expression was significantly lower than peritumor expression. Low GALNT4 expression was associated with poor overall and relapse-free survival (p = 0.001 and 0.004, respectively). Intratumor GALNT4 expression, which negatively correlated with tumor size (p = 0.032), necrosis (p = 0.013) and TNM stage (p = 0.017), was an independent prognostic indicator for overall and relapse-free survival (HR 3.088, p = 0.020 and 2.173, p = 0.047, respectively). Extending the TNM staging system according to GALNT4 expression showed a better prognostic value for overall and relapse-free survival (AUC 0.786, p = 0.029 and 0.761, p = 0.040, respectively).
CONCLUSIONS: Intratumor GALNT4 expression is a potential independent prognostic factor for overall and relapse-free survival in patients with clear cell renal cell carcinoma. Further external validation and functional analysis should be performed to assess its potential prognostic and therapeutic value in patients with clear cell renal cell carcinoma.
Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  carcinoma; kidney; mortality; polypeptide N-acetylgalactosaminyltransferase; prognosis; renal cell

Mesh:

Substances:

Year:  2014        PMID: 24769034     DOI: 10.1016/j.juro.2014.04.084

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer.

Authors:  Songyang Wu; Hongyong He; Hao Liu; Yifan Cao; Rochen Li; Heng Zhang; He Li; Zhenbin Shen; Jing Qin; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-03-06       Impact factor: 8.110

Review 2.  N-acetylgalactosaminyltransferases in cancer.

Authors:  Muhammad Ramzan Manwar Hussain; Daniel C Hoessli; Min Fang
Journal:  Oncotarget       Date:  2016-08-16

3.  Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection.

Authors:  Zhi Li; Sohsuke Yamada; Ying Wu; Ke-Yong Wang; Yun-Peng Liu; Hidetaka Uramoto; Kimitoshi Kohno; Yasuyuki Sasaguri
Journal:  Oncotarget       Date:  2016-08-23

4.  ppGalNAc-T4-catalyzed O-Glycosylation of TGF-β type Ⅱ receptor regulates breast cancer cells metastasis potential.

Authors:  Qiong Wu; Cheng Zhang; Keren Zhang; Qiushi Chen; Sijin Wu; Huang Huang; Tianmiao Huang; Nana Zhang; Xue Wang; Wenli Li; Yubo Liu; Jianing Zhang
Journal:  J Biol Chem       Date:  2020-12-03       Impact factor: 5.157

5.  Prognostic Significance of Alternative Splicing Genes in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma.

Authors:  Xiaoyu Wang; Weichun Tang; Yilin Lu; Jun You; Yun Han; Yanli Zheng
Journal:  Int J Gen Med       Date:  2021-11-09

Review 6.  Altered glycosylation in cancer: A promising target for biomarkers and therapeutics.

Authors:  Divya Thomas; Ashok Kumar Rathinavel; Prakash Radhakrishnan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-11-04       Impact factor: 10.680

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.